期刊文献+

BCL10高表达引起脾脏边缘带B细胞抗凋亡而致其体内增生 被引量:2

Over-expression of BCL10 is Anti-apoptotic to Splenic Marginal Zone B Cells Resulting in Their Hyperplasia
在线阅读 下载PDF
导出
摘要 目的以Eμ-BCL10转基因(transgenic,Tg)小鼠为模型研究BCL10高表达引起MALT淋巴瘤发病的分子机制。方法 PCR鉴定Eμ-BCL10转基因小鼠,Western blotting检测BCL10转基因蛋白的表达,组织学方法显示BCL10Tg小鼠脾脏MALT淋巴瘤的前体细胞-边缘带(marginalzone,MZ)B细胞扩增,流式细胞仪鉴定脾脏边缘带B细胞并分离出这群B细胞用于抗凋亡机制的研究,使用Annexin V-FITC/PI双染法经流式细胞仪检测边缘带B细胞凋亡情况。结果 PCR鉴定BCL10转基因阳性(Tg/+)小鼠,Western blotting证明内源性BCL10蛋白在Tg/+和非转基因野生型(widetype,WT)小鼠中表达的水平相同;BCL10Tg/+小鼠BCL10蛋白的表达量是WT小鼠的2倍。组织学染色显示,BCL10Tg/+小鼠脾脏增生的B细胞可能是边缘带B细胞,将这群B细胞用CD21、CD23染色并经流式细胞仪分析,证明这群增生的B细胞正是CD21high/CD23low的边缘带B细胞。为了进一步研究边缘带B细胞的增生机制,采用CD43、CD23双染,然后通过流式细胞仪分选出BCL10Tg/+以及WT小鼠的边缘带B细胞。BCL10Tg/+小鼠的边缘带B细胞群约30%可以在含5%FBS的RPMI-1640中存活1周以上,而WT小鼠的边缘带B细胞群在第3天几乎全部死亡(P<0.01),这一结果说明,BCL10的高表达引起边缘带B细胞的抗凋亡效应。Anti-IgM诱导边缘带B细胞凋亡实验结果显示,BCL10高表达保护anti-IgM诱导的细胞凋亡。结论 BCL10高表达引起脾脏边缘带B细胞扩增,扩增的B细胞具有抗凋亡特性,这种抗凋亡特性影响抗原受体信号传导途径。这些结果可以在一定程度上解释因BCL10高表达而引起的MALT淋巴瘤的发病分子机制。 Objective To explore the molecular mechanisms of MALT lymphoma caused by BCL10 over-expression. Methods BCL10 transgenic (Tg ) mice were identified by BCL10 transgene specific PCR,and BCL10 protein expression were verified by Western Blot. MALT lymphoma precursor cells-marginal zone(MZ) B cells expansion in BCL10 Tg mice were defined by histology methods and flow cytometry analysis,anti-apoptotic effects of separated MZ B cells were examined with Annexin V-FITC / PI staining. Results The BCL10 Tg/+ mice used in the experiment were verified by transgene specific PCR. Protein expression of transgene is almost at the same level as endogenous BCL10,which means,in Tg/+ mice,BCL10 protein has doubled than that in non-transgenic WT mice. By histology,we found B cells expansion in Tg/+ mice which look like MZ B cells morphologically. By verification with CD21,CD23 staining followed by flow cytometry analysis,it is proven those expanded B cells are CD21high/CD23low MZ B cells. To investigate the mechanisms causing the MZ B cells expansion,we separate the MZ B cells from both Tg/+ and WT control mice by cell sorting with CD43,CD23 double staining. About 30% separated MZ B cells from Tg/+ mice can survive at least up to one week in RPMI-1640 containing 5% FBS,but those from WT mice almost all died at day 3(P0.01),this result means over-expression of BCL10 in MZ B cells causes anti-apoptotic effects to those cells. We studied pathways of anti-apoptotic that BCL10 might be involved by inducing apoptosis with anti-IgM,BCL10 over-expression protect anti-IgM caused cell apoptosis. Conclusion Over-expression of BCL10 causes expansion of MZ B cells which have anti-apoptotic property. This property is involved antigen receptor pathway. These results may partially answer the molecular mechanisms of MALT lymphoma with t(1; 14) (p22; q32) chromosome translocation.
出处 《首都医科大学学报》 CAS 北大核心 2010年第3期353-358,共6页 Journal of Capital Medical University
基金 国家自然科学基金(30872933) 北京市自然科学基金(7092011) 北京市教育委员会科技发展计划项目(KM200910025004)资助项目~~
关键词 BCL10转基因小鼠 MALT淋巴瘤 边缘带B细胞 抗凋亡 BCL10 transgenic mice MALT lymphoma marginal zone B cell anti-apoptosis
作者简介 Corresponding author, E-mail: quangeng_zhang@ yahoo. com. cn
  • 相关文献

参考文献10

  • 1Bertoni F,Zucca E.Delving deeper into MALT lymphoma biology[J].J Clin Invest,2006,116:22-26.
  • 2Zhang Q,Siebert R,Yan M,et al.Inactivating mutations and overexpression of BCL10,a caspase recruitment domain-containing gene,in MALT lymphoma with t(1; 14) (p22; q32)[J].Nat Genet,1999,22:63-68.
  • 3Willis T G,Jadayel D M,Du M Q,et al.Bcl10 is involved in t(1; 14) (p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types[J].Cell,1999,96:35-45.
  • 4Xue L,Morris S W,Orihuela C,et al.Defective development and function of Bcl10-deficient follicular,marginal zone and B1 B cells[J].Nat Immunol,2003,4:857-865.
  • 5Thieblemont C,Berger F,Dumontet C,et al.Mucoss-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed[J].Blood,2000,95:8022-8051.
  • 6Li Z,Wang H,Xue L,et al.Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone(MZ) B-cell expansion as a precursor to splenic MZ lymphoma[J].Blood,2009,114:4158-4168.
  • 7Su H,Bidère N,Zheng L,et al.Requirement for Caspase-8 in NF-kB Activation by Antigen Receptor[J].Science,2005,307:1465-1468.
  • 8van Oers N S,Chen Z J.Kinasing and clipping down the NF-kappa B trail[J].Science,2005,308:65-66.
  • 9Lin X,Wang D.The roles of CARMA1,Bcl10,and MALT1 in antigen receptor signaling[J].Seminars in Immunol,2004,16:429-435.
  • 10Noels H,Somers R,Liu H,et al.Auto-Ubiquitination-Induced Degradation of MALT1-API2 Prevents BCL10 Destabilization in t(11;18)(q21;q21)-Positive MALT Lymphoma[J].PLoS One,2009,4:e4822.

同被引文献15

  • 1Villadolid J, Laplant KD, Markham MJ, et al. Hepatitis B reacti vation and rituximab in the oncology practice[J]. Oneologist, 2010,15(10) :1113- 1121.
  • 2Lok AS, McMahon BJ. Chronic hepatitis B: update 2009[J]. Hepatology, 2009,50(3) : 661-662.
  • 3Niitsu N, Hagiwara Y, Tanae K, et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy[J]. J Clinoncol,2010,28(34):5097-5100.
  • 4Wang F,Xu RH,Luo HY,et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma[J]. BMC Cancer, 2008,8 : 115.
  • 5Tsutsumi Y, Ogasawara R, Kamihara Y, et al. Rituximab administra tion and reactivation of HBV[J].Hepat Res Treat ,2010:182067.
  • 6European Association For The Study Of The Liver. EASL Clini- cal Practice Guidelines: management of chronic hepatitis B[J]. J Hepatol,2009,50(2) :227- 242.
  • 7Poison J,Lee WM. AASLD position paper: the management of acute liver faiiure[J]. Hepatology,2005,41(5) :1179-1197.
  • 8何建锋,张彦明,段会娟,曹金锁,张德礼.人天然免疫基因BCL10的猪同源物的识别、克隆与初步表达分析[J].遗传,2008,30(6):747-754. 被引量:5
  • 9肖焕擎,王强,孙政.原发性结肠淋巴瘤的诊断和治疗[J].国际外科学杂志,2009,36(5):302-305. 被引量:1
  • 10郑文,谢彦,王小沛,刘卫平,张运涛,涂梅峰,林宁晶,宋玉琴,平凌燕,应志涛,邓丽娟,王洁,朱军.恶性淋巴瘤伴乙型肝炎病毒感染率调查分析[J].中华肿瘤防治杂志,2010,17(6):417-419. 被引量:10

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部